<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04138927</url>
  </required_header>
  <id_info>
    <org_study_id>C-935788-058</org_study_id>
    <nct_id>NCT04138927</nct_id>
  </id_info>
  <brief_title>A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia</brief_title>
  <official_title>A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigel Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigel Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are:

        -  To establish the efficacy of fostamatinib in placebo crossover subjects with warm
           antibody autoimmune hemolytic anemia (wAIHA)

        -  To determine the ability to maintain a response in subjects receiving fostamatinib for
           wAIHA
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 30, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Durable Response</measure>
    <time_frame>104 weeks</time_frame>
    <description>A primary efficacy endpoint is the proportion of subjects who achieve a durable hemoglobin response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Durable Response and Hemoglobin Response</measure>
    <time_frame>104 weeks</time_frame>
    <description>The proportion of any subjects who achieve a durable response and have a hemoglobin response at 48 weeks of exposure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Response by Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of placebo crossover subjects who have achieved a hemoglobin response by week 24 of this study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Hemoglobin Response</measure>
    <time_frame>24 Weeks</time_frame>
    <description>The proportion of any subjects who achieve a partial hemoglobin response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Hemoglobin Value at Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Median hemoglobin value at week 24 of this study, for placebo crossover subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median change from baseline in hemoglobin at week 24</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Median change from baseline in hemoglobin at week 24 of this study for placebo crossover subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durable Response and Maintain a Hemoglobin Response at 24 and 36 Weeks</measure>
    <time_frame>36 Weeks</time_frame>
    <description>The proportion of any subjects who achieve a durable response and maintain a hemoglobin response at 24 and 36 weeks of exposure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Warm Antibody Autoimmune Hemolytic Anemia</condition>
  <arm_group>
    <arm_group_label>Fostamatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who at any time during the C-935788-057 study achieved a hemoglobin response in the absence of rescue in the previous 4 weeks or a steroid dose greater than baseline will continue at their current dose (100mg or 150 mg) and regimen in the extension study.
All other subjects who enter the extension study will initially receive fostamatinib 100 mg PO bid. Starting at Week 4, the initial fostamatinib dose of 100 mg PO bid will be increased to fostamatinib 150 mg PO bid if subjects have adequately tolerated the study drug, based on the investigator's judgment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib disodium</intervention_name>
    <description>Fostamatinib (100mg PO bid or 150 mg PO bid)
The dose may be reduced at any time to a dose as low as fostamatinib 100 mg PO qd or matching placebo if dose limiting adverse events are observed.</description>
    <arm_group_label>Fostamatinib</arm_group_label>
    <other_name>R935788</other_name>
    <other_name>Fostamatinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be willing and able to give written informed consent by signing an IRB
             approved Informed Consent Form prior to undergoing any study-specific procedures.

          2. Subject must have completed all 24 weeks of participation in the study C-935788-057.

        Exclusion Criteria:

        1. Any subject who discontinued participation in Study C-935788-057 prior to Week 24.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>John Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Trials Unit</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4201</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Nikolaas</name>
      <address>
        <city>Sint-Niklaas</city>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno Interni hematologicka a onkologicka klinika</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava Klinika hematoonkologie</name>
      <address>
        <city>Ostrava</city>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD Multiprofile Clinic Consilium Medulla</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M. Zodelava Hematology Centre, Tbilisi</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Georgia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>October 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2019</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>wAIHA</keyword>
  <keyword>Warm Antibody Autoimmune Hemolytic Anemia</keyword>
  <keyword>Warm Autoimmune Hemolytic Anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

